Table 1 Clinicopathological and demographic characteristics for 785 endometrial cancer MoMaTECa trial patients

From: DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer

Characteristics Mean s.d., min–max
Age (years) 66.4 11.1, 28–98
Parityb 2.2 1.4, 0–8
Characteristics Number of cases Percentage
Information available preoperatively
Curettage DNA ploidy   
 Diploid 565 72.0
 Aneuploid 162 20.6
 Tetraploid 52 6.6
 Polyploid 6 0.8
Information available postoperatively
Histological subtypec   
 Endometrioid carcinomad 656 83.8
 Serous carcinoma 56 7.2
 Clear cell carcinoma 31 4.0
 Carcinosarcoma 27 3.4
 Undifferentiated carcinoma/other 13 1.7
Histological differentiatione   
 Grade 1 281 36.0
 Grade 2 272 34.9
 Grade 3 227 29.1
Myometrial invasionf   
 <50% 453 64.0
 ≥50% 255 36.0
FIGO stage (2009 revision)   
 I 608 77.5
 II 58 7.4
 III 91 11.6
 IV 28 3.6
Lymph node metastasisg   
 No 512 87.7
 Yes 72 12.3
  1. Abbreviation: FIGO=International Federation of Gynaecology and Obstetrics.
  2. aMolecular Markers in Treatment of Endometrial Cancer.
  3. bParity information missing for 10 patients.
  4. cHistological subtype missing for two patients.
  5. dIncluding cases with squamous differentiation.
  6. eHistological differentiation missing for five patients.
  7. fData for myometrial infiltration not available for 77 patients.
  8. gLymph node status evaluated in 584 patients.